Gilead Sciences saw two straight days of 5% gains after announcing a successful phase 2 trial for its combo next-gen interferon free pill for curing hepatitis C. It looks as if the company's combination treatment of sofosbuvir and ledipasvir, is on track to be the new standard of care after posting a 95% cure rate.
In the following video, health-care analyst David Williamson discusses what this means for investors in the big biotech and its two closest competitors.
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.